• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cartesian Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    5/30/25 7:02:49 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNAC alert in real time by email
    rnac-20250530
    0001453687false00014536872025-05-302025-05-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
     
    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): May 30, 2025
     
    CARTESIAN THERAPEUTICS, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware 001-37798 26-1622110
    (State or other jurisdiction
    of incorporation)
     (Commission
    File Number)
     (IRS Employer
    Identification No.)
     
    7495 New Horizon Way, Frederick, MD 21703
    (Address of principal executive offices)(Zip Code)
     
    (301) 348-8698
    Registrant’s telephone number, including area code
     
    N/A
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock (Par Value $0.0001)RNACThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company o

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 8.01 Other Information.
    On May 30, 2025, Cartesian Therapeutics, Inc. issued a press release announcing the enrollment of the first participant in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit
    No.
     Exhibit Description
      
    99.1
    Press release of Cartesian Therapeutics, Inc. issued on May 30, 2025.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     CARTESIAN THERAPEUTICS, INC.
      
      
    Date: May 30, 2025By:/s/ Carsten Brunn, Ph.D.
      Carsten Brunn, Ph.D.
      President and Chief Executive Officer

    Get the next $RNAC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNAC

    DatePrice TargetRatingAnalyst
    12/19/2024$42.00Buy
    BTIG Research
    8/6/2024Buy
    TD Cowen
    7/2/2024Outperform → Perform
    Oppenheimer
    6/4/2024$50.00Outperform
    Oppenheimer
    5/24/2024$40.00Buy
    Mizuho
    4/23/2024$2.00 → $54.00Buy
    H.C. Wainwright
    4/23/2024$39.00Outperform
    Leerink Partners
    More analyst ratings